Top Markets
Coin of the day
Merck & Co., Inc. Merck & Co., Inc.

Merck & Co., Inc.

MRK
Rank in Stocks #40
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Share Price
$151.22
Market Cap
$373.47B
Change (1 day)
11.61%
Change (1 year)
78.05%
Country
US
Trade Merck & Co., Inc. (MRK)

Category

P/E ratio for Merck & Co., Inc. (MRK)
P/E ratio as of August 2026 TTM: 107.81
According to Merck & Co., Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 107.81. At the end of 2024 the company had a P/E ratio of 14.72.
P/E ratio history for Merck & Co., Inc. from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 107.81 645.57%
2025 14.46 -1.74%
2024 14.72 -98.11%
2023 778.71 3,924.61%
2022 19.35 30.21%
2021 14.86 -46.79%
2020 27.92 23.57%
2019 22.60 -25.59%
2018 30.37 -49.75%
2017 60.43 53.54%
2016 39.36 24.80%
2015 31.54 144.60%
2014 12.89 -59.36%
2013 31.72 65.59%
2012 19.16 9.91%
2011 17.43 -85.89%
2010 123.55 2,069.42%
2009 5.70 -28.19%
2008 7.93 -78.40%
2007 36.72 79.85%
2006 20.42 41.90%
2005 14.39 23.34%
2004 11.67 -19.12%
2003 14.42 -15.38%
2002 17.04 -3.27%
2001 17.62 -41.63%
2000 30.19 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
39.54 -63.33%
US
30.10 -72.08%
US
70.28 -34.81%
US
22.25 -79.36%
CH
22.23 -79.38%
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.